Belfer Institute, Sanofi-Aventis Partner on Oncology Targets

The institute and the drugmaker will collaborate to identify and validate oncology targets, and Sanofi-Aventis will then do further work to develop therapeutic agents against the targets and related biomarkers.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.